- (2015): Muller Y+, Rev Med Suisse (French) 11(469), 826 [REVIEW]
- (2020): Zelmat Y+, Drug Saf Mar, Epub ahead of print [REVIEW]
- (2018): Tandan M+, Int J Antimicrob Agents Apr, Epub ahead of print [REVIEW]
Adverse reactions attributed to entire drug class 'Antibiotic; fluoroquinolone'
January 2024: The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) further limited the use of fluoroquinolone antibiotics. The class of antibiotics should now only be used in situations when other antibiotics that are commonly recommended for the infection are inappropriate, e.g. when other options are contraindicated or the infection is proving resistant. Previous guidance stated that fluoroquinolones should not be prescribed for non-severe or self-limiting infections.
Please login to view adverse reactions.
Cardiac disorder / cardiac dysfunction
- (2019): Bonaldo G+, Pharmacoepidemiol Drug Saf Aug, Epub ahead of print [REVIEW]
- (2015): Daneman N+, BMJ Open 5(11), Epub
- (2015): Ramachandran G+, Drug Saf 38(3), 253 (life threatening)
Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))
- (2023): Algaidi SH+, J Cardiovasc Pharmacol Jul, Online ahead of print
- (2021): Wee I+, Sci Rep 11(1), 11073 [REVIEW] (association)
- (2020): Aspinall SL+, Pharmacol Res Perspect 8(6), e00664 (association)
- (2018): Tandan M+, Int J Antimicrob Agents Apr, Epub ahead of print [REVIEW]
Neurological adverse effect / neurological deficit
- (2021): Ellis DE+, Pharmacoepidemiol Drug Saf Mar, Online ahead of print (association)
Neuropsychiatric / neuropsychological adverse effect
- (2022): Guan Y+, Front Pharmacol Oct (e-Collection) (ADR signal mining techniques)
- (2014): Mattappalil A+, Clin Ther 36(11), 1489 [REVIEW]
- (2025): Omrani MA+, J Psychopharmacol Jun, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
- (2015): Muller Y+, Rev Med Suisse (French) 11(469), 826 [REVIEW]
- (2014): Etminan M+, Neurology 83(14), 1261
- (2020): Palma-Alvarez RF+, Actas Esp Psiquiatr 48(3), 126-37 [REVIEW]
- (2014): Mostafa S+, J Clin Psychopharmacol 34(4), 483 [REVIEW]
- (2018): Tandan M+, Int J Antimicrob Agents Apr, Epub ahead of print [REVIEW]
- (2019): Yang HY+, Ther Clin Risk Manag 15, 389
- (2018): Tandan M+, Int J Antimicrob Agents Apr, Epub ahead of print [REVIEW]
- (2010): Stahlmann R+, Drugs Aging 27(3), 193 [REVIEW]
Dyspepsia / functional dyspepsia (indigestion) (see also gastroparesis)
- (2010): Stahlmann R+, Drugs Aging 27(3), 193 [REVIEW]
Gastrointestinal perforation / perforated colon / gastric perforation
- (2017): Hsu SC+, PLoS One 12(9), Epub
- (2018): Tandan M+, Int J Antimicrob Agents Apr, Epub ahead of print [REVIEW]
- (2010): Stahlmann R+, Drugs Aging 27(3), 193 [REVIEW]
- (2018): Tandan M+, Int J Antimicrob Agents Apr, Epub ahead of print [REVIEW]
- (2010): Stahlmann R+, Drugs Aging 27(3), 193 [REVIEW]
Musculoskeletal adverse effects
- (2021): Huruba M+, Sci Rep 11(1), 14375 [REVIEW]
- (2019): Kim Y+, Sci Rep 9(1), 20156
- (2016): Rosa B+, Clin Case Rep 4(7), 678 [REVIEW]
- (2015): Daneman N+, BMJ Open 5(11), Epub
- (2015): Muller Y+, Rev Med Suisse (French) 11(469), 826 [REVIEW]
- (2015): Daneman N+, BMJ Open 5(11), Epub
- (2015): Muller Y+, Rev Med Suisse (French) 11(469), 826 [REVIEW]
- (2014): Mancano MA, Hosp Pharm 49(6), 498
- (2012): Huber M+, Med Monatsschr Pharm (German) 35(12), 436 [REVIEW]
Adverse effects / adverse reactions
- (2025): Jonville-Béra AP+, Infect Dis Now Apr, Online ahead of print [REVIEW]
- (2023): Barberán J+, Rev Esp Quimioter Dec, Online ahead of print [REVIEW]
- (2019): Etminan M+, Pediatr Infect Dis J 38(3), 268-270
- (2016): Trubiano JA+, J Allergy Clin Immunol Pract 4(6), 1187 (cutaneous)
